ESPE2015 Free Communications Growth-promoting therapies (6 abstracts)
Safety and Effectiveness of Increlex® Therapy in Children with Laron Syndrome and Enrolled in the European Increlex® Growth Forum Database in Europe
Peter Bang a , Michel Polak b , Joachim Woelfle c , Aude Houchard d & Caroline Sert d
aFaculty of Health Sciences, Linköping University, Linköping, Sweden; bHôpital Universitaire Necker Enfants Malades, Université Paris Descartes, Paris, France; cChildren’s Hospital, University of Bonn, Bonn, Germany; dIPSEN Pharma, Boulogne Billancourt, France
Background: The post-authorisation registry, European Increlex® Growth Forum Database (EU-IGFD), initiated in December 2008, collects data in children receiving Increlex (mecasermin (rDNA origin) injection) for growth failure, including Laron syndrome (LS) (severe primary IGF1 deficiency with confirmed GH-receptor mutation).
Objective and hypotheses: Report safety and effectiveness data in children with LS.
Method: Multicentre, open-label observational study, eCRF data collection.
Results: As of 2nd October 2014, nine countries enrolled 205 patients (115 naïve-prepubertal), including 29 LS patients (13 naïve-prepubertal). In LS patients (vs non-LS), 45% were females (vs 34%), 48% treatment-naïve (vs 69%). Mean (95% CI) treatment duration (days): 1413 (1190; 1636) (vs 916 (837; 995)); median dose (μg/kg BID): 40 at treatment initiation (both subgroups), 105 (vs 120) at year 1, 120 at year 2. Naïve-prepubertal LS patients had significantly higher Δ height SDS at year 1, vs naïve-prepubertal non-LS (linear regression, P=0.006).
Targeted adverse events (TAEs) were reported in 69% LS patients (vs 36% non-LS); most frequently hypoglycaemia (41% vs 13%), lipohypertrophy (21% vs 9%), tonsillar hypertrophy (17% vs 5%), and otitis media (14% vs 3%). LS was a predictive factor for hypoglycaemia (OR (CI 95%): 0.21 (0.09;0.50); P<0.001).
| na | Height SDS | na | Δ Height SDS | |
| LS patients | ||||
| Baseline | 26 | −5.22 (1.63) | ||
| Year 1 | 23 | −4.46 (1.88) | 22 | 0.50 (0.61) |
| Year 2 | 22 | −4.51 (1.72) | 20 | 0.77 (0.79) |
| Naïve-prepubertal | ||||
| Baseline | 12 | −5.80 (1.60) | ||
| Year 1 | 10 | −4.76 (2.09) | 9 | 0.77 (0.54) |
| Non-LS patients | ||||
| Baseline | 163 | −3.50 (1.04) | ||
| Year 1 | 139 | −3.19 (1.10) | 134 | 0.32 (0.44) |
| Year 2 | 102 | −2.99 (1.24) | 99 | 0.57 (0.62) |
| Naïve-prepubertal | ||||
| Baseline | 97 | −3.42 (0.95) | ||
| Year 1 | 84 | −3.03 (0.95) | 81 | 0.36 (0.40) |
| aAvailable at timepoint. | ||||
Conclusion: Height SDS increase was higher in LS patients vs non-LS and this was significant at year 1 in the naïve-prepubertal subgroup; however, they remained shorter. TAEs were more frequent in LS patients; LS was identified as predictive factor for hypoglycaemia.
Declaration of interest: A Houchard and C Sert: employees of Ipsen. M Polak and J Woelfle: advisory boards for Ipsen and Novo Nordisk.
Funding: This work and the study on which it is based were supported by Ipsen.
Article tools
My recent searches
My recently viewed abstracts
ESPE Abstracts
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more